We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


COVID-19 Vaccine Distribution Challenges

Video   Apr 30, 2021 | Taken from Yale School of Medicine


A year into the COVID-19 pandemic, the approval of not only one but several effective vaccines has given us reason to be hopeful. But we now face a new set of logistical and ethical challenges in our unprecedented effort to inoculate the global population.

“This is the largest mass vaccination campaign and the most rapid one in human history,” says Andrew Heinrich, a lecturer at the Yale School of Public Health. “And that creates supply chain challenges and distribution challenges.” The first hurdle standing between these life-saving vaccines and the general public are a myriad of supply chain complexities – from manufacturing to transportation to storage. Although significant, these supply chain issues are all surmountable, says viral epidemiologist and Director of the Yale Institute for Global Health, Dr. Saad B. Omer. The larger concern is that these supply chain constraints make it impossible for us to vaccinate everyone at once. Which means we must make strategic and equitable decisions about who to vaccinate first. “We are in a position where it’s necessary to decide who to vaccinate first and all of humanity is benefited when those at greatest risk get vaccinated first,” says Heinrich.

Watch this video to learn more about overcoming distribution challenges and how equity plays a crucial role in determining the success of the COVID-19 vaccine rollout.

More Information

Recommended Videos

Potential Therapeutic Uses of Cannabinoids With Professor Roger Pertwee


Much of what we know about the cannabis plant and its effects on the human body has only been formally discovered in the past 60 years. A good deal of these pioneering investigations have involved today's Teach Me in 10 guest: Roger Pertwee, an emeritus professor at the University of Aberdeen.


Amersham™ brand ImageQuant™ 800 GxP biomolecular imager – Cytiva


Sensitive, flexible CCD-based imagers designed to support FDA 21 CFR Part 11 EU GMP Annex 11 regulations


Study Identifies Several Existing Drugs As Potential COVID-19 Therapies


Mining the world’s most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the coronavirus that’s driving the ongoing global pandemic.



Like what you just watched? You can find similar content on the communities below.

Biopharma Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free